| Autor: |
Fontecilla NM, Khanna T, Bayan CY, Antonov NA, Geskin LJ |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of drugs in dermatology : JDD [J Drugs Dermatol] 2019 Jan 01; Vol. 18 (1), pp. 103-104. |
| Abstrakt: |
Novel immunotherapies including antibodies to programmed death ligand 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) have become common therapies for neoplasms including metastatic melanoma and non-small cell lung cancer (NSCLC). Dermatologic toxicity is the most common adverse event associated with these immunotherapies. We report a case of bullous pemphogoid (BP) in a patient receiving combination durvalumab and tremelimumab, two newer immunotherapy checkpoint inhibitors under investigation in phase III trials. J Drugs Dermatol. 2019;18(1):103-104. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
